High BCR-ABL/GUSIS Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib
Background The approval of second-generation tyrosine kinase inhibitors (TKIs) for the first
line treatment of Chronic Myeloid Leukemia (CML) has generated a need for early molecular …
line treatment of Chronic Myeloid Leukemia (CML) has generated a need for early molecular …
[PDF][PDF] THE USE OF QUANTITATIVE REAL-TIME PCR IN MONITORING TREATMENT RESPONSE–A NEW STANDARD OF CARE IN CHRONIC MYELOID LEUKEMIA …
K TĂTAR, H IONIŢĂ - EDITORIAL BOARD - medinevolution.umft.ro
Chronic myeloid leukemia (CML) is a myeloproliferative disorder, characterized by a specific
chromosomal aberration, the Philadelphia [Ph] chromosome. The Ph chromosome is the …
chromosomal aberration, the Philadelphia [Ph] chromosome. The Ph chromosome is the …
Monitoring disease response to tyrosine kinase inhibitor therapy in CML
TP Hughes, S Branford - ASH Education Program Book, 2009 - ashpublications.org
The remarkable progress made in the treatment of chronic myeloid leukemia (CML) over the
past decade has been accompanied by steady improvements in our capacity to accurately …
past decade has been accompanied by steady improvements in our capacity to accurately …
A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after …
H Kitamura, Y Tabe, T Ai, K Tsuchiya, M Yuri… - PLoS …, 2019 - journals.plos.org
Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 fusion protein, encoded by the
Philadelphia chromosome, have drastically improved the outcomes for patients with chronic …
Philadelphia chromosome, have drastically improved the outcomes for patients with chronic …
[引用][C] Serial molecular monitoring of BCR-ABL mRNA using quantitative real-time RT-PCR in patients with CML treated with Imatinib (STI 571) as first-or second-line …
F Neumann, C Herold, N Gattermann, K Habersang…
Optimizing early prediction of outcome in CML using the exact decline of BCR-ABL transcript levels within 3 months of imatinib treatment as a prognostic marker
B Hanfstein, V Shlyakhto, M Lauseker, R Hehlmann… - 2013 - ashpublications.org
Introduction Early assessment of BCR-ABL transcript levels at 3 months allows the
prediction of survival and may serve as a trigger for treatment intensification in CML patients …
prediction of survival and may serve as a trigger for treatment intensification in CML patients …
[HTML][HTML] High BCR-ABL Levels At Diagnosis Are Associated with Unfavorable Responses to Imatinib Mesylate.
Abstract 2790 The approval of second-generation tyrosine kinase inhibitors (TKIs) for the
first line treatment of Chronic Myeloid Leukemia (CML) has generated a need for early …
first line treatment of Chronic Myeloid Leukemia (CML) has generated a need for early …
[HTML][HTML] The BCR-ABL transcript levels at 3 and 6 months predict the long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib mesylate: a …
F Castagnetti, G Gugliotta, M Breccia, G Specchia… - Blood, 2012 - Elsevier
Abstract Abstract 1678 Background. Imatinib mesylate (IM) is the therapeutic standard for
chronic myeloid leukemia (CML), but nilotinib and dasatinib, at least in selected patients …
chronic myeloid leukemia (CML), but nilotinib and dasatinib, at least in selected patients …
Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase
J Moravcová, V Zmeková, H Klamová, J Voglová… - Leukemia research, 2004 - Elsevier
Kinetics of BCR-ABL transcript levels were determined in 19 patients with chronic myeloid
leukemia (CML) treated with imatinib for chronic (CP) or accelerated phase (AP). Patients …
leukemia (CML) treated with imatinib for chronic (CP) or accelerated phase (AP). Patients …